Pharmaceuticals company Jubilant Pharmova announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations for Q4FY25 was Rs 1,929 crore, a 10% increase compared to Rs 1,759 crore in Q4FY24. Total Income for Q4FY25 was Rs 1,941 crore, a 9% increase compared to Rs 1,773 crore in Q4FY24. EBITDA for Q4FY25 was Rs 357 crore, a 23% increase compared to Rs 289 crore in Q4FY24. EBITDA Margin for Q4FY25 stood at 18.4%, expanding by 210 bps from 16.3% in Q4FY24. Reported PAT for Q4FY25 was Rs 151 crore, a 345% increase compared to a loss of Rs 62 crore in Q4FY24. Normalized PAT for Q4FY25 was Rs 139 crore, a 127% increase compared to Rs 61 crore in Q4FY24. FY25 Financial Highlights: Revenue from Operations for FY25 was Rs 7,628 crore, an 8% increase compared to Rs 7,060 crore in FY24. Total Income for FY25 was Rs 7,678 crore, an 8% increase compared to Rs 7,103 crore in FY24. EBITDA for FY25 was Rs 1,434 crore, a 24% increase compared to Rs 1,153 crore in FY24. EBITDA Margin for FY25 stood at 18.7%, expanding by 220 bps from 16.5% in FY24. Reported PAT for FY25 was Rs 572 crore, a 1,050% increase compared to Rs 50 crore in FY24. Normalized PAT for FY25 was Rs 506 crore, a 112% increase compared to Rs 239 crore in FY24. Commenting on the Company’s performance in FY25, Shyam S Bhartia, Chairman Jubilant Pharmova and Hari S Bhartia, Co-Chairman & Non-Executive Director, said, “We are pleased to announce revenue of Rs 7,235 crore. in FY25, growth of 8% over last year. We delivered robust revenue growth across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables and CRDMO businesses. EBITDA grew by 24% to Rs 1,230 crore. on the back of strong operating performance across all business units. EBITDA margins for the year expanded by 220 basis points. Reported PAT grew by 1,050% to Rs 836 crore., while normalised PAT grew by 112% to Rs 415 crore. on the back of improved operating performance and reduced finance cost. Net Debt / EBITDA reduced from 2.5x in Mar’24 to 1.1x in Mar’25 on the back of voluntary debt prepayment of USD 125 million in FY25. In Feb’2025, we outlined our Vision 2030, which is to double our revenues from FY24 to FY30, improve EBITDA margins to 23% to 25% range, reduce Net debt to zero and grow Return on Capital to high teens. Our FY25 financial performance takes us one-step closer to our Vision. During the year, the Company started distributing Pylarify®, an industry leading prostate cancer diagnostic imaging agent from PET radiopharmacies, completed Media Fills on Line 3 in CDMO Sterile Injectables, added strategic capabilities in the area of Biologics and Antibody drug conjugates in Drug Discovery, reached profitability in the Generics business and dosed first patients in JBI-802 and JBI-778 clinical trials. The large innovator pharma companies, for their US requirements, are now looking to create an alternate manufacturing site in the US as a risk management measure in the event of tariff imposed by the US govt. Therefore, the company is starting to see excellent traction in the CDMO Sterile Injectable business for new lines in the Spokane facility. We expect to reach peak utilisation for Line 3 in 3 years from start of commercial production vs 4 years, expected earlier.” Result PDF